Where does Reprieve Cardiovascular, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Reprieve Cardiovascular, Inc. ranks #21,685 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Reprieve Cardiovascular, Inc. hold?

Reprieve Cardiovascular, Inc. holds 13 US utility patents granted between 2021 and 2025, spanning 5 technology areas.

What is Reprieve Cardiovascular, Inc.'s Innovation Score?

Reprieve Cardiovascular, Inc. has an Innovation Score of 47.6 out of 100 (top 18% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Reprieve Cardiovascular, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Reprieve Cardiovascular, Inc..

What does claim depth mean for Reprieve Cardiovascular, Inc.'s patents?

Reprieve Cardiovascular, Inc.'s patents average 17.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Reprieve Cardiovascular, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Reprieve Cardiovascular, Inc.

Q: What technology areas does Reprieve Cardiovascular, Inc. focus on?

Reprieve Cardiovascular, Inc.'s top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 13 patents, ranking #542 of 3,490 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

USPTO PatentsView assignee record - 13 granted patents across 5 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Reprieve ranks #21,685 of 49,997 tracked US assignees by granted-patent volume, with 13 patents across 5 technology areas.

#21,685
of 49,997 US assignees by volume: Top 18%
by Innovation Score (47.6/100): 17.7
avg claims per patent

USPTO PatentsView assignee plate

Corpus R21685 · US Corporation #21,685 · 13 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 13 grants
MID-PACK #21,685/49,997
PHOTO-FINISH Redarc PTY
CPC-NARROW A61M · 5 areas
INNOV-PAR 47.6/100
CLAIMS-RICH 17.7 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Redarc Technologies PTY Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Reprieve’s 47.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.1 pts (19%) Velocity 20.0 pts (42%) Breadth 7.9 pts (17%) Claim depth 10.6 pts (22%)

Qualcomm Incorporated · highest

85
Reprieve Cardiovascu… · this assignee

48
3D Lighting… · lowest

7

What this shows Reprieve's Innovation Score is 47.6/100 (top 18% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Reprieve?

Each dot is one of Reprieve’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Reprieve’s own 17.7 claims/patent is ABOVE the 15.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Reprieve vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Reprieve's grants concentrate

Reprieve Cardiovascular, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2021. By volume, Reprieve sits between Redarc Technologies PTY Ltd and Reyco Granning, LLC.

Reprieve's three-year grant acceleration

Reprieve Cardiovascular, Inc. shows 8 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Redarc PTY

13
Refai L L C

13
Reishauer

13
Renishaw (Ireland)

13
Restek

13
Reviva Pharmaceut…

13
Revivo Medical

13
Reyco Granning

13
Reprieve Cardiova… ◀

13

What this shows Reprieve holds 13 patents at rank #21,665, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Reprieve

By rank, the assignees closest to #21,665 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Reprieve's primary technology class.

Reprieve's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

48 Top 18% higher than 82% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Reprieve Cardiovascular, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	1	7.7%
2022	2	15.4%
2023	3	23.1%
2024	3	23.1%
2025partial year	4	30.8%

Which technologies does Reprieve Cardiovascular, Inc. patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 13

A61B - DIAGNOSIS; SURGERY; Identification 11

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 6

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 3

G16Z - Information AND Communication Technology [ICT] Specially Adapted FOR Specific Application Fields, NOT Otherwise Provided FOR 2

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Reprieve Cardiovascular, Inc.'s patent record in context - here's where to go next.

Reprieve Cardiovascular, Inc.'s lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 100% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #21,685 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Reprieve Cardiovascular, Inc. against Redarc Technologies PTY Ltd, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 47.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.